{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:04:18Z","timestamp":1781816658704,"version":"3.54.5"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.canlet.2024.216660","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T02:50:53Z","timestamp":1705978253000},"page":"216660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Delivery of CD47-SIRP\u03b1 checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma"],"prefix":"10.1016","volume":"585","author":[{"given":"Qizhong","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hexian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongdong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiping","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.216660_bib1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216660_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2024.216660_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","article-title":"Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience","volume":"77","author":"Holstein","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216660_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2024.216660_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome inhibitor drugs","volume":"60","author":"Fricker","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.canlet.2024.216660_bib6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2024.216660_bib7","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple myeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2024.216660_bib8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s40265-020-01311-1","article-title":"Isatuximab: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216660_bib9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-016-0540-0","article-title":"Elotuzumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216660_bib10","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216660_bib11","first-page":"332","article-title":"FDA approves first BCMA-targeted CAR-T cell therapy","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216660_bib12","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216660_bib13","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","article-title":"Teclistamab: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216660_bib14","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","article-title":"Elranatamab: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216660_bib15","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s40265-023-01945-x","article-title":"Talquetamab: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2024.216660_bib16","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1182\/blood-2008-09-179762","article-title":"A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation","volume":"113","author":"Gupta","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216660_bib17","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216660_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11523-017-0538-x","article-title":"The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in, multiple myeloma","volume":"13","author":"Sanchez","year":"2018","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.canlet.2024.216660_bib19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216660_bib20","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI81603","article-title":"CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer","volume":"126","author":"Weiskopf","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2024.216660_bib21","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.7150\/thno.40860","article-title":"Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis","volume":"10","author":"Hu","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2024.216660_bib22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","article-title":"Targeting CD47 for cancer immunotherapy","volume":"14","author":"Jiang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216660_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.768115","article-title":"Significance of CD47 and its association with tumor immune microenvironment heterogeneity in ovarian cancer","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216660_bib24","doi-asserted-by":"crossref","first-page":"148","DOI":"10.7150\/thno.79367","article-title":"Blockade of dual immune checkpoint inhibitory signals with a CD47\/PD-L1 bispecific antibody for cancer treatment","volume":"13","author":"Wang","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2024.216660_bib25","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2024.216660_bib26","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41568-019-0183-z","article-title":"Phagocytosis checkpoints as new targets for cancer immunotherapy","volume":"19","author":"Feng","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2024.216660_bib27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2024.216660_bib28","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.7150\/ijbs.60782","article-title":"CD47\/SIRP\u03b1 pathway mediates cancer immune escape and immunotherapy","volume":"17","author":"Jia","year":"2021","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2024.216660_bib29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216660_bib30","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.ymthe.2021.01.006","article-title":"A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC","volume":"29","author":"Du","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216660_bib31","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1182\/blood.2021013901","article-title":"Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression","volume":"139","author":"Cao","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216660_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2022.03.011","article-title":"Blocking CD47 promotes antitumour immunity through CD103(+) dendritic cell-NK cell axis in murine hepatocellular carcinoma model","volume":"77","author":"Wang","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2024.216660_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13045-022-01385-2","article-title":"SIRP\u03b1-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47\/SIRP\u03b1 signal pathway via blocking the \"don't eat me\" signal and activating the \"eat me\" signal","volume":"15","author":"Yu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216660_bib34","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216660_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2024.216660_bib36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-139655","article-title":"AO-176, a highly differentiated clinical stage anti-CD47 antibody, exerts potent anti-tumor activity in preclinical models of multiple myeloma as a single agent and in combination with approved therapeutics","volume":"136","author":"Wilson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216660_bib37","article-title":"TTI-622-01: a phase 1a\/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including multiple myeloma","volume":"40","author":"Patel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2024.216660_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/fon-2022-0975","article-title":"A phase II multi-arm study of magrolimab combinations in patients with relapsed\/refractory multiple myeloma","volume":"19","author":"Paul","year":"2023","journal-title":"Fut. Oncol."},{"key":"10.1016\/j.canlet.2024.216660_bib39","article-title":"Allogeneic CAR cell therapy-more than a pipe dream","volume":"11","author":"Caldwell","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2024.216660_bib40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"'Off-the-shelf' allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2024.216660_bib41","doi-asserted-by":"crossref","first-page":"17002","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2024.216660_bib42","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T cells, and universal CAR T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2024.216660_bib43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to Be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.216660_bib44","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-20-3863","article-title":"CRISPR\/Cas9-Engineered universal CD19\/CD22 dual-targeted CAR-T cell therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"27","author":"Hu","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216660_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2024.216660_bib46","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/j.ymthe.2022.06.006","article-title":"Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy","volume":"30","author":"Tipanee","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2024.216660_bib47","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2024.216660_bib48","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12951-019-0468-0","article-title":"Nanobody-horseradish peroxidase fusion protein as an ultrasensitive probe to detect antibodies against Newcastle disease virus in the immunoassay","volume":"17","author":"Sheng","year":"2019","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2024.216660_bib49","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12951-019-0568-x","article-title":"Nanobody-horseradish peroxidase and -EGFP fusions as reagents to detect porcine parvovirus in the immunoassays","volume":"18","author":"Lu","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2024.216660_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12951-021-00768-w","article-title":"Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein","volume":"19","author":"Lu","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2024.216660_bib51","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2024.216660_bib52","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T cells to Be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.216660_bib53","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41596-020-0294-8","article-title":"Engineering primary T cells with chimeric antigen receptors for rewired responses to soluble ligands","volume":"15","author":"Chang","year":"2020","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.canlet.2024.216660_bib54","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold","volume":"284","author":"Vincke","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2024.216660_bib55","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cr.2016.142","article-title":"CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.canlet.2024.216660_bib56","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.canlet.2024.216660_bib57","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2017.329","article-title":"Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond","volume":"32","author":"Chim","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2024.216660_bib58","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.canlet.2024.216660_bib59","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3324\/haematol.2019.227579","article-title":"Targeting CD47\/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma","volume":"105","author":"Rastgoo","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2024.216660_bib60","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1158\/2326-6066.CIR-19-0734","article-title":"Improved antitumor efficacy of chimeric antigen receptor T cells that secrete single-domain antibody fragments","volume":"8","author":"Xie","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2024.216660_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003737","article-title":"Delivery of CD47 blocker SIRP\u03b1-Fc by CAR-T cells enhances antitumor efficacy","volume":"10","author":"Chen","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2024.216660_bib62","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1182\/blood.2022016101","article-title":"Potentiating antibody-dependent killing of cancers with CAR T cells secreting CD47-SIRP\u03b1 checkpoint blocker","volume":"141","author":"Dacek","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216660_bib63","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1073\/pnas.85.13.4852","article-title":"Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity","volume":"85","author":"Steplewski","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216660_bib64","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1126\/science.1118948","article-title":"Divergent immunoglobulin g subclass activity through selective Fc receptor binding","volume":"310","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.canlet.2024.216660_bib65","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2024.216660_bib66","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.4049\/jimmunol.1200356","article-title":"Crosstalk between human IgG isotypes and murine effector cells","volume":"189","author":"Overdijk","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.216660_bib67","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of human IgG subclasses to mouse Fc gamma receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.canlet.2024.216660_bib68","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Shultz","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2024.216660_bib69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/imm.12290","article-title":"Signal-regulatory protein \u03b1 from the NOD mouse binds human CD47 with an exceptionally high affinity-- implications for engraftment of human cells","volume":"143","author":"Kwong","year":"2014","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2024.216660_bib70","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","article-title":"Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex","volume":"157","author":"King","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.canlet.2024.216660_bib71","doi-asserted-by":"crossref","first-page":"13022","DOI":"10.1073\/pnas.1000475107","article-title":"Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD\/SCID\/IL2r gamma(null) humanized mice","volume":"107","author":"Shultz","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2024.216660_bib72","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/cei.12051","article-title":"Human T cells depend on functional calcineurin, tumour necrosis factor-\u03b1 and CD80\/CD86 for expansion and activation in mice","volume":"172","author":"S\u00f8ndergaard","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.canlet.2024.216660_bib73","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2024.216660_bib74","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1038\/s41467-021-26003-6","article-title":"An oncolytic virus expressing a full-length antibody enhances antitumor innate immune response to glioblastoma","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2024.216660_bib75","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1158\/1078-0432.CCR-21-1248","article-title":"Targeting Fc receptor-mediated effects and the \"don't eat me\" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer","volume":"28","author":"Tian","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524000545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383524000545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T04:35:55Z","timestamp":1719635755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383524000545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":75,"alternative-id":["S0304383524000545"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216660","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of CD47-SIRP\u03b1 checkpoint blocker by BCMA-directed UCAR-T cells enhances antitumor efficacy in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.216660","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216660"}}